Pfizer (PFE) is expected to report Q4 earnings on Tuesday, February 1 before the market open with a conference call scheduled for 10 am ET.
GuidanceAnalysts are looking for EPS of 46c on revenue of $16.97B. The consensus range is 43c-49c for EPS, and $16.44B-$17.98B for revenue, according to First Call. Positive catalysts may be seen coming from sales in Lyrica and Enbrel with generic erosion in older drugs possibly mitigating those gains. As the company digests acquisitions, investors will be looking for indications of cost reductions. On the Q3 earnings call Pfizer management indicated that the company was on track to achieve those anticipated cost reductions. Also, of particular concern for the company and investors is the impending Lipitor patent expiration in October.
Analyst ViewsOn January 18, Wells Fargo upgraded the large cap pharmaceuticals sector to Overweight. The firm has Outperform ratings on Pfizer with a valuation range of $20-$23.
No comments:
Post a Comment